Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
Stroke is one of the commonest encountered brain and neurological disorders worldwide. Stroke management has had a major shift in the last 50 years and precisely since the discovery and approval of thrombolysis as an acute management followed by multiple trials on mechanical thrombectomy and its approval. Yet, Stroke is as old as the history of mankind. Historically stroke symptoms’ description is older than the descriptions of the Greco-Roman civilization (500 BC – 800 AD). Before Stroke, the term apoplexy was described in ancient civilizations and evidence of suffering and managing it is preserved within the mummies, inscriptions, and papyri of the Egyptian civilization, clay tablets of the Mesopotamian civilization, medical books of the Chinese civilization, and although physicians and scientists consider the Greco-Roman civilization the base for modern medicine, yet the golden age of Islam (800 – 1200 AD) might have shared more in identifying bases of stroke. The European Renaissance beginning from 1400 AD with its famous anatomists and physicians greatly contributed too to stroke localization and vascular supply.
Conclusions
As medicine and science are in a continuous chain from the past to the future through the present, the current comprehensive review highlights the major important and documented shifts in the history of stroke over more than 4500 years starting from ancient civilizations BC up to 2024 AD.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
BC
Before Christ
AD
Anno Domini
ICA
Internal carotid artery
ACA
Anterior cerebral artery
MCA
Middle cerebral artery
PCOM
Posterior communicating
ACOM
Anterior communicating
VA
Vertebral artery
BA
Basilar artery
PCA
Posterior cerebral artery
tPA
Tissue plasminogen activator
MT
Mechanical thrombectomy
ESUS
Embolic stroke of undetermined source
Introduction
The link between the heart and the brain has existed since the dawn of civilizations [1, 2], it was initially along the context of psychology, the soul, and which is superior to the other including a belief that the senses as hearing and sight pass through the bloodstream to the heart first and then the heart transfers its perception about what is heard and seen to the brain where it distributes its content to the rest of the body through the neurons to act accordingly [1].
It was even believed that the brain, not the heart, acts as a pump of what was called a vital spirit which is transferred to it through blood vessels coming out of the more divine organ, the heart. The brain distributes such spirit to the body's organs through its mesh of nerves [1].
Anzeige
“The heart is the barracks of the soul” was the belief of many philosophers and ancient physicians providing life, motion, and emotion to the brain and sequentially the body. There was a belief that obstruction to the vital spirit from reaching the brain would cause brain damage termed apoplexy [3].
In modern medicine, the heart is crucial in pumping oxygenated blood. This blood besides other etiological causes might carry a source of brain attack or what is best known today as stroke or cerebrovascular stroke [3].
The link between the heart and the brain goes beyond philosophy to involve treatment, the coronaries are usually managed first before similar attempts are made to the cerebral circulation.
Science and medicine are a continuous chain one ought to know the past, the basics of evolvement to predict the future and link both through the present. In the current review, stroke is represented since antiquities when the word apoplexy was the common term up to the term cerebrovascular stroke nowadays with a focus on facts and fiction about the etiology and pathology behind stroke, its presentation and its description in antiquities, the discovery of the circle of Willis and the role of different philosophers and physicians in it, and discoveries in the management of stroke along 4500 years are highlighted (Fig. 1).
Fig. 1
Timeline of Stroke from antiquity to modernity. Black typing: historical events, red typing: Circle of Willis discoveries, Green typing: medication discoveries, Blue typing: Important clinical trials
Stroke extends earlier than the Greco-Roman civilization which is usually thought to be the founder of modern medicine. In his historical review on stroke, Karenberg presented an illustrated figure of sources of stroke in antiquities dating to 500 BC [4]. Yet, this is not the case as the description of stroke or apoplexy dates to the ancient Egyptian civilization whether in discovered papyri in tombs or temple inscriptions as the one dating 2455 BC on the tomb of the Vizier Westptah [5].
Medicine and surgery extend to the early civilizations and the basis of modern medicine is based in many aspects on the Greco-Roman philosophers and Muslim physicians who based some of their theories on earlier knowledge from the Egyptian, Chinese, Sumerians, Babylonians, Assyrians, and Persian civilizations [6].
Egyptian civilization
An Egyptian mummy (2680 years) representing a possible case of left hemiparesis was discovered in Luxor. After working on the body radiologically and forensically, it was concluded that it belonged to a female in her late twenties to early forties. The mummy was taking a typical position of left hemiparesis with an extensive contracted and adducted shoulder, face facing down, flexion of the left arm and forearm placed on the chest with over flexed wrist up to twisting of the left hand, the left leg was overextended as donated by placing its fibula more anteriorly than the right leg and the foot was planter flexed. The body of the mummy was fixed with sticks to keep it in an erect position. A walking stick was found beside the mummy [7].
Etiologically modern medicine can place a differential diagnosis ranging from infectious diseases to cerebrovascular insults which is more favorable as other diseases usually in earlier times were fatal within a short time frame and not affording time to live with a disability up to contracture deformities [7, 8].
Despite no direct link in this discovered young female stroke patient to cardiovascular insults yet being young female and as current clinical practice return stroke in young to either vessel-to-vessel embolization, cardiac source, or vasculitis secondary to autoimmune, hypercoagulable states or thrombophilia disorders; an etiological cardiovascular cause can be considered in this 747–656 BC discovered mummy [7, 8].
Egyptian papyri mentioned hemiparesis and quadriparesis yet returning them to spine conditions [9]. It is worth mentioning that the heart and the vascular system were described in some detail yet in a primitive way in the ancient Egyptian civilization. Egyptians considered the heart the source of all body fluids and is connected to different body parts through 22 identified vessels, they knew that the heart and the lung are connected and that air through both is transmitted to the rest of the body [10, 11].
In Ancient Egypt pulsation was thought to originate from blood vessels, and arterial aneurysms were described and were managed through cautery through which excessive pulsation is stopped [11].
In the nineteenth century, atherosclerosis was discovered in royal pharaonic mummies. Further analysis was performed using the Horus Study. It was found that atherosclerosis was present in 85% of examined mummies the oldest dating 1981 BC and results were 38% common among different civilizations making atherosclerosis a common disorder in antiquities at least in the high social class [10, 12].
Anzeige
In the Horus study, carotid atherosclerosis was present in 8 of 52 studied mummies, while it was a common finding in the coronaries and the carotids in 2. In 6 mummies atherosclerosis was found within the aorta [12].
The mummy of Menephtah (1213–1203 BC) was found to be afflicted with atheromatous lesions within the aorta. Despite being old enough when he ruled Egypt which might reason for atherosclerosis other mummies who showed atherosclerosis in the Horus study were of different ages [12, 13].
Nowadays, it is proven that inflammation and inflammatory disorders including autoimmune conditions accelerate vasculitis and atherosclerosis. Inflammatory disorders might date to ancient civilizations. Another explanation that is not related to hypertension or diabetes which are not ruled out nor accused, since their prevalence is not known in ancient Egypt is smoke from the cooking fire that generates proatherogenic methane and gelatinase [14].
Myocardial infarction and angina were well known in the Egyptian civilization and were linked to eminent death as written in the Ebers papyrus, yet whether angina was dreadful up to death or acted as a comorbid condition to stroke is still mysterious in ancient medicine [15].
Anzeige
Sumerian, Babylonian, and Assyrian civilizations
Unlike the Egyptians, the Mesopotamian civilization which is nowadays modern Iraq did not describe the inner organs of the body and there are no mummies to return to for autopsy. Yet, like the Egyptians, the Mesopotamians outweighed the heart and considered it the center of the body and its main organ [16]. As the Egyptians, they were acquainted with pulsation and identified the heart as its origin and that pulse cessation was equivalent to death [17].
What makes the Mesopotamian civilization a major source for the localization of stroke is the precise description of symptoms on clay tablets. In tablet 27, there is a detailed description of unilateral facial weakness and paralysis on one side of the body. Lateralizing signs were well known as there was a link between the development of aphasia, right-sided weakness, and left hemisphere lesions, while left-sided weakness without aphasia was linked to the right hemisphere. Meanwhile, the Assyrians had a prognostic idea that the left hemisphere injuries that were accompanied by aphasia usually had a less favorable outcome and that if there was a motion preserved along the distal extremities without dysphasia then a favorable outcome was proposed [16, 18]. This resembles what modern medicine accounts for in the National Institutes of Health stroke scale scores (NIHSS) [19].
Genetic load as a direct causative cause of stroke was not considered except in modern science [20, 21], yet the Mesopotamians were the first to introduce genetics in stroke more than 2500 years, documented in a timeline between 692 and 681 BC that two ruling brothers (Humban-Nimena III and Humban-Haltash I) died out of apoplexy stating that one presentation was speech affection “mouth seized to talk” [22].
Chinese civilization
Stroke in its ancient term apoplexy has been mentioned in the context of comorbid neurological disorders as post-stroke epilepsy since 475 BC. In a Chinese book for diseases and prescriptions, 52 diseases were identified including different forms of stroke that range from mild to severe with disturbed consciousness. As the Mesopotamians, the Chinese linked a stroke with speech affection, those with mild speech affection were considered treatable, while those with loss of verbal abilities were considered untreatable reflecting that although ancient medicine was not able to identify major vessels and its link to a massive stroke, yet they were able to identify massive stroke through its signs which donate cortical affection [23].
Anzeige
A Chinese medical book by Zhang Zhongjing in the second century AD was considered the first source classifying stroke/apoplexy into mild and massive forms, where the classification was mild if the consciousness was maintained and with sensory or motor affection in the extremities along one side of the body with or without difficulty in speech or deviation of mouth. Meanwhile, a massive form was in case of disturbed conscious level with paralysis and unclear speech. Owing to his classification, Zhongjing was considered Hippocrates of China [23].
The Greco-Roman apoplexy theories
The Greco-Roman theories of stroke/apoplexy extended between 500 BC and 800 AD and began with Hippocrates and ended with Galen.
Although modern medicine considers Greco-Roman medicine the basis for modern science yet once digging in-depth into the theories behind diseases that the Greco-Roman philosophers were up to one will deny many. One theory that prevailed along 1200 years was that functions of the brain were located within the ventricular system rather than the brain parenchyma. Diseases were thought to originate because of an imbalance between four fluids present in the body and the brain chambers (humoral theory of Hippocrates) [6].
Yet, the Greco-Roman theories were accurate in some basic links linking stroke/apoplexy symptoms and severity as they identified stroke affecting breathing and severity as well as fatality which is nowadays explained based on brainstem compression and herniation [6].
Anzeige
The Muslim golden age
From 800 to 1200 AD, Muslims led the world in different fields of science and medicine. A new relationship emerged between the heart and the brain, both were considered vital organs, and stroke/apoplexy might originate from the heart and affect the brain which is cardioembolic stroke.
Haly Abbas and Ibnisina (Avicenna in Latin) stated that the ventricular system might be congested and filled with a mixture of fluids stated earlier by Hippocrates and Galen, stating that it might be filled with blood. This was the basics of what is known as hemorrhagic stroke and interventricular hemorrhage. Brain edema was introduced by Ibnisina stating that in severe stroke the brain is congested and the ventricles are occluded [6].
Muslim physicians also elaborated on how the heart was connected to the brain through blood vessels and that one of the fluids stated earlier in the humoral theory or even thick blood might occlude these vessels causing a stroke. This might be the earliest facts behind thrombosis, and embolization [6].
Rhazes introduced the fact that stroke was a result of damage to the brain parenchyma, not the ventricles and that the ventricular system involvement is just a part of the pathology taking place within the brain parenchyma [6].
Anzeige
One of the thoughts of Galen was the permeability of the intracardiac septum and that this was the way through which blood was transferred from the lungs to the left ventricle and then to the rest of the body. This theory was denied by Ibn al-Nafis in describing the pulmonary circulation. Ibn al-Nafis also explained that the arterial and the venous sides of the pulmonary circulation are interconnected within the lung by narrow vessels which were later termed the pulmonary capillaries [24].
Galen's theory is only rational in modern medicine in pathological conditions that might cause paradoxical emboli to the brain as in the case of patent foramen ovale [25, 26].
Al-Akhawayni Bukhari (Joveini in Latin) described how the brain is supplied by two main vessels that pass on either side of the neck (the carotids in modern medicine), on entering the skull, they are divided into a network to supply the entire brain. This was seven centuries before the identification of the circle of Willis [27].
By the fifteenth century, the time of the fall of Al-Andalus the golden age of Islam began to subside, and the European Renaissance took over:
In 1599, the term stroke was first used in the English literature to reflect striking suddenly, initially, it reflected hitting something or an unexpected sudden important event, and since cerebrovascular accidents are sudden, unexpected and what follows differs from what proceeds in activities of daily living so stroke as a regular English noun began to reflect what Cambridge dictionary defines as a sudden change in the blood supply to a part of the brain, with its consequences on the loss of functions of the affected part as the ability to move [28, 29].
For both Greek and Chinese Hippocrates, the term apoplexy was the preferred term that reflects hemiparesis secondary to a brain insult and until years ago the term apoplexy was still preferred by some physicians to reflect the dramatic and sudden nature of the insult resembling thunder-lightning [30].
What Hippocrates and Galen as well as what Muslim physicians and philosophers considered a cause of stroke/apoplexy which was the thickening of fluids or blood viscosity with an increase of wastes within such fluids was later modified in the eighteenth century with the identification and approval of the blood pressure concept [6, 30]. Before the identification of blood pressure and its management, stroke/apoplexy was managed by blood letting out to return the balance between the fluids of the body and remove waste products and this is the cupping in the Muslim traditions, which was later modified to the venesection introduced by Osler in 1892 as a way of reducing blood pressure after stroke [6, 30, 31].
Osler’s theory was not abandoned except in 1935 when venesection was no longer considered in dealing with stroke/apoplexy. Reducing blood pressure is one of the main aspects of secondary prevention of stroke in modern medicine yet it is not a matter of removing waste products or restoring the balance between body fluids as thought earlier [6, 32, 33].
The pathogenesis of stroke was not discovered in full until recently and even today some causes of stroke are still unknown and termed embolic stroke of undetermined source [34, 35]. Many lay people still believe in superpowers and supernatural events as a cause behind their illnesses which is much more common in disorders that are bizarre in presentation as epilepsy yet for centuries up to the nineteenth century black magic and superpowers were considered a cause of stroke [6, 30, 36].
In the European Renaissance era, there were no scales that could be relayed upon to reflect the severity and outcome of stroke as the current ones like the modified Rankin scale and the NIHSS [19, 37], yet as ancient civilizations used to link symptoms to severity and mortality such as speech arrest or breathing affection, in Napoleon’s era suffering stroke for a second time was of worse outcome and a third was usually considered fatal as what Corvisart warned Napoleon about [30, 38].
In the eighteenth century and as bedside medicine began to emerge, risk factors began to have a role in explaining the etiological causes of stroke. Modern medicine continues nowadays to approve special habits and risks such as a short neck and apnea, a sedentary life with an absence of physical activity, a diet rich in carbohydrates, alcohol intake, and smoking. In addition, in the eighteenth century, it was stated that “living a moderate life is protective and an excess of anything is dangerous and might provoke apoplexy” [39, 40].
As for recovery, the modern neuroplasticity concept was not in full action in the eighteenth century, and in the nineteenth century, the prognosis of stroke/apoplexy was guarded if no recovery began to appear within 3 months and if contractures happened to emerge [30, 41].
By the end of the eighteenth century, physicians began to approach diseases through pathology and disruption of anatomy through autopsy [42]. With the discovery of cerebral circulation by Willis and the identification of areas responsible for expression and later comprehension by Broca and Wernicke the term cerebrovascular disease emerged, and apoplexy was discarded [43]. Another explanation for the emergence of cerebrovascular disease term instead of apoplexy which used to reflect the dramatic nature of the illness is that autopsies began to show that the commonest cause of apoplexies was ischemia rather than hemorrhage and although it is of sudden nature it is not drastically as in the case of hemorrhage [4].
Discovering the arterial polygon of the brain
known as the circle of Willis, the anastomotic arterial tree at the base of the skull that supplies the brain with blood and provides anatomical protection against the development of stroke through the redirection of blood flow through its unique anastomosis.
Surprisingly such arterial anastomosis is not truly a circle nor directly credited to Sir Thomas Willis.
Since antiquity and during the Greco-Roman civilization dissections were not routinely done on humans yet occasionally were performed on animals and what is found within animals was reflected on humans [44].
Galen who is best known by Western civilization as one of the founders of anatomy discovered a mesh of complex blood vessels on the base of the skull of a bull and termed it the rete mirabile “wonderful net”, claiming to be present in the human brain.
The rete mirabile was an undeniable fact until the European Renaissance when the dissection of human bodies was approved and at this period which was nearly thirteen centuries later the rete mirabile was denied [44, 45].
The first anatomist to deny Galen’s wonderful net was Andreas Vesalius in the sixteenth century and owing to true human body dissection he reached a frank conclusion that there was no rete mirabile along the base of the human skull. Moreover, Vesalius dissected the area surrounding the pituitary gland, despite his inability to identify its content yet, he localized the two sleeping arteries (the internal carotid arteries”ICA”) and within some of his illustrations, a bifurcated right ICA was drawn which might be one of the first known variants in the later on termed circle of Willis, also segment A1 and A2 of the anterior cerebral artery (ACA) were represented, the middle cerebral artery (MCA), and the posterior communicating artery (PCOM) [44, 46, 47].
Another variant that was unintentionally described by Vesalius was the absence of an anterior communicating artery (ACOM). So, credit must be given to Vesalius for providing a scientific path for further discoveries of the arterial supply of the brain with two variants [44].
Gabriel Fallopius followed Vesalius and described a portion of the posterior arterial tree, he described the union of the two vertebral arteries (VA) and then their division as well as the union of the ICAs, described some of the branches originating from what later on identified as basilar artery (BA) as well as describing the PCOM, yet what Fallopius failed in was his inability to identify the anastomosis of vessels. The contribution of Fallopius was the initial identification even by chance of the BA perforators [44].
Within the second half of the sixteenth and the first quarter of the seventeenth centuries, the full representation of the arterial polygon was demonstrated, first, was Giulio Casserio who died leaving 86 anatomical drawings, followed by Adriaan van den Spiegel who again left an anatomical treatise to his successor Daniel Bucretius who illustrated it and presented the first well-described arterial polygon with a complete connection. In this era, another variant was described which was weak left PCOM as it seemed to be formed of two thin vessels [44, 48, 49].
Later, Johann Vesling described the arterial polygon in a nearly perfect way yet did not recognize the posterior cerebral artery (PCA) and was still considering the smaller branches and perforators as rete mirabile [50, 51].
Six years earlier to Willis's description, Johann Jakob Wepfer von Schaffhausen described in detail the arterial polygon with an emphasis on the splitting and anastomosis of the ICA, ACA, VA. Von Schaffhausen also focused on the perforators and their anastomosis. If the arterial polygon is not to be named after von Schaffhausen as some scholars suggest then his credit would be the proper identification of branching and anastomosing arteries forming the brain arterial tree rather than the ordinary vasculature joining artery to vein as in the rest of the body [44].
Thomas Willis working together with Richard Lower, and Thomas Millington was able to describe in full detail with illustrations the arterial polygon at the base of the skull, and with the ability to inject dye into the carotids the anastomosis and the collateral circulation was also identifiable. Willis as von Schaffhausen highlighted the value of the arterial anastomotic tree in its ability to overcome obstructed vessels by redirecting blood flow through other pathways protecting the brain in case of an occluded artery. It was not before 100 years later that Sir Thomas Willis's name was placed on the arterial polygon and named the circle of Willis [44].
Management of stroke from antiquities onwards
Being a disorder that has been known, since the dawn of civilizations attempts were made to overcome its burden. Attempts at management in antiquities were not much preserved either on the temples, papyri, or tablets. Yet as it was conceived as a strike from superpowers it was mostly managed by priests and was considered a punishment [30, 36].
Diseases including stroke in the Greco-Roman era were conceived as an imbalance between the four fluids which was the basis of the humoral theory of Hippocrates. Meanwhile, Galen conceived stroke as an obstruction to the spirit that passes from the heart into the rete mirabile at the skull base. Such obstruction was not considered secondary to blood clot development rather it was due to the organization of one of the body fluids. Muslims in the golden age assumed that thick blood caused occlusion of vessels and might be the reason behind the stroke [6].
Although rejected by Paracelsus in the sixteenth century, the humoral theory was still the approved explanation up to the nineteenth century and only competed by the punishment or curse theories [52].
Being secondary to an excess of one of the four fluids or failure to get it out of the body through different passages including defecation, stroke was managed by bizarre ways including enemas and suppositories to restore the balance between the fluids of the body. The only rational idea in management at that time was to get rid of the waste blood through cupping and later by venesection [6].
Natural remedies and ingredients were applied orally, nasally, or topically in different stages of stroke, such natural remedies were described and used as a common practice by Ibnisina in Canon of Medicine. Despite these ingredients not anymore used in modern medicine yet they were used based on their role in healing, neuroprotection, antioxidant, blood pressure lowering, and fibrinolytic role as being identified in modern medicine [53].
Ingredients that were used and modern medicine classifies as antioxidants are (Pistacia lentiscus L., Piper longum L., Rosa damascena Mill, Zingiber officinale Roscoe) as for neuroprotective agents (Citrus medica L., Matricaria chamomilla Blanco, Piper nigrum L.), blood pressure lowering (Zingiber officinale Roscoe, Ferula persica Willd.) and fibrinolytic (Elettaria cardamomum (L.) Maton). The Canon of Medicine of the tenth century continued to be a source of diagnosis and management of different disorders including stroke in Europe up to the seventeenth century [53].
Secondary prevention was achieved with the discovery of antiplatelets and statins and with the identification of atherosclerosis [13, 54, 55]. Acetylsalicylic acid (Aspirin) was first introduced in 1899 as a potent treatment for pain and fever and in 1900 was patented. It took 60 years for scientists to prove in the 1960s that aspirin acts on platelet aggregation and prevents thrombosis in laboratory experimental animals. In 1978 aspirin showed a role in reducing the risk of stroke and soon was approved in clinical trials to be effective against stroke [56, 57]. Meanwhile, 2 years earlier in 1976 statins were discovered yet it was not until 1984 that the first statin was approved [54].
In the 1960s, dipyridamole was introduced as a coronary vasodilator. Soon, it was approved as an antithrombotic that can inhibit platelet adhesiveness [58].
In 1972 and onwards through the 1980s, the irreversible platelet ADP antagonist ticlopidine was developed and was proved to be effective in stroke by 1989 [59].
In 1988, cilostazol which is a phosphodiesterase III inhibitor was manufactured in Japan as a derivative of cilostamide that prevents platelet reactivity and aggregation and acts as a vasodilator. In 2015, cilostazol was approved in Japan for secondary prevention of stroke, and in 2021, it was further approved in Asia as an add-on to other antiplatelets in non-cardioembolic strokes or transient ischemic attacks with intracranial or extracranial arterial stenosis or multiple vascular risk factors yet, it is not approved in Europe and only has a level of evidence C in USA [60].
By the 1990s, clopidogrel as a derivative of ticlopidine was developed and showed efficacy in clinical protection against ischemic insults [61]. Meanwhile, monoclonal antibodies against glycoprotein IIb/IIIa receptors were also introduced in the 1990s, preventing fibrinogen and von Willebrand factor from binding to glycoprotein IIb/IIIa receptors on activated platelets yet mostly used in acute coronary syndromes and cardiac catheters and are administered intravenously to induce rapid onset and short duration [62].
Following clopidogrel which was considered the first antiplatelet targeting adenosine diphosphate receptor P2Y12 came the second and the third forms, Ticagrelor and Prasugrel although being used in coronary syndromes their use in stroke is minimal owing to some adverse effects although some trials have adapted them [61, 63, 64].
It was not until the recognition of the pathophysiological and etiological causes of stroke by Fisher and Adams which were atherosclerosis, thrombosis, embolism, small vessel disease with its associated lipo hyalinosis as well as vasospasm and hemodynamic instabilities when anticoagulants mainly heparin was introduced for acute stroke [65]. Yet, after the results of the TOAST trial, heparin was no longer fit or considered effective in the management of acute strokes [66].
Acute management of stroke
acute stroke management began with the emergence of tPA and is continuing up to the use of artificial intelligence [67] (Table 1).
Table 1
Most important acute stroke management clinical trials in the modern years
Study/Clinical Trial
Abbreviation
Years
Type of Management
Time of intervention
Value and outcome
Tissue Plasminogen Activator for Acute Ischemic Stroke—The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group [68]
3 h from onset
Patients treated with tPA have 30% minimal or no disability at 90 days compared to placebo
6.4% of patients had symptomatic intracerebral hemorrhage
Improvement in clinical outcome despite extending the window up to 4.5 h with a number needed to treat 14 patients for 1 patient to have a favorable outcome
The early treatment of aspirin and extended-release dipyridamole versus aspirin alone for treatment of minor ischaemic stroke within 24 h of stroke-onset [74]
EARLY
2010
Medical
90-day extended-release dipyridamole and aspirin
Establishment of safety in early initiation of dual therapy compared to late (after 7 days) initiation of therapy
Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events [75]
CHANCE
2015
Medical
Loading clopidogrel followed by clopidogrel for 90 days with aspirin for 21 days compared to aspirin alone for 90 days
The benefit was shown in the loading group in reducing stroke for up to 1-year follow-up
Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands [76]
MR CLEAN
2015
MT following IV-thrombolysis
6 h from onset
MT was effective and safe
Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times [77]
ESCAPE
2015
MT following IV-thrombolysis or following best medical management
12 h from onset
MT improved outcomes and had a reduced mortality rate
Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting within 8 h of Symptom Onset [78]
REVASCAT
2015
MT following IV-thrombolysis
8 h from onset
MT reduced disability and improved outcomes
Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke [79]
SWIFT-PRIME
2015
MT following IV-thrombolysis
6 h from onset
MT improved functional outcomes
Extending the Time for Thrombolysis in Emergency Neurological Deficits – Intra Arterial [80]
EXTEND-IA
2015
MT following IV-Thrombolysis
6 h from onset
MT had better reperfusion, recovery, and functional outcomes
The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke
IV-Thrombolysis based on perfusion MRI or perfusion CT
4.5–9 h
tPA achieved better functional outcomes
There was a risk of intracranial hemorrhage yet the benefit exceeded the risk
Extending the Time for Thrombolysis in Emergency Neurological Deficits [87]
EXTEND
2019
IV-Thrombolysis based on CT perfusion
4.5–9 h
tPA achieved better functional outcomes
There was a risk of intracranial hemorrhage yet the benefit exceeded the risk
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [88]
POINT
2019
Medical
Clopidogrel and aspirin < 12 h from the vascular event
Dual therapy is associated with reduced ischemic events yet with a risk of major hemorrhage
For 1000 patients, 15 ischemic events will be prevented, and 5 will bleed
Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core [89]
ANGEL
ASPECT
2023
MT versus medical management
ASPECT radiological score rather than duration
No significant interaction was found between intervention and medical management in large infarct core
Randomized Controlled Trial to Optimize Patient’s Selection for Endovascular Treatment in Acute Ischemic Stroke [90]
SELECT 2
2023–2024
MT versus medical management
ASPECT radiological score or volume in MRI or CT perfusion rather than duration
MT had better functional outcomes at 1 year compared to medical care alone
Effect of an Artificial Intelligence-Based Clinical Decision Support System on Stroke Care Quality and Outcomes in Patients with Acute Ischemic Stroke [91, 92]
GOLDEN BRIDGE II
2024
Artificial intelligence in the decision-making of stroke management
Follow up for 3 months
Artificial intelligence is of benefit in stroke care quality and outcome
Tissue plasminogen activator (tPA) was discovered by Desire Collen and later, was cloned and used in myocardial infarction in the 1980s by Diane Pennica as well as some trials on administering it to major occluded vessels as the carotids and basilar arteries. Before approval, it was used on animal models [67].
Before the NINDS I and II trial in 1995–1996, there were plenty of studies on applying pro-urokinase intraarterial, using a small dose of tPA, as well as the ECASS study that applied tPA within 6 h of identification of ischemic stroke coupled with heparin [67, 68].
1996 passed without approving tPA on a wide scale although approved by the Food and Drug Administration, as there were scientific and personal conflicts based on the negative results that ECASS and ECASS II and streptokinase had in 1995 and 1998 [67].
In 2007, the Safe Implementation of Thrombolysis in Stroke–Monitoring Study Registry (SITS–MOST) and the ECASS III results were released. At that timepoint in the history of stroke, tPA became widely used in Europe and worldwide [73].
Since then, a major shift in the management of stroke occurred, with different trials all aiming to reduce the burden of stroke as the trials that targeted transient ischemic attacks or minor stroke and aimed at reducing the risk of incidence of stroke at 90 days through the use of antiplatelets of different forms and combination as well as durations with endpoints of bleeding and/or stroke development as FASTER, EARLY, MATCH, CHARISMA, and CHANCE [70‐72, 74, 75].
Meanwhile, on the track of catheters applied to acute coronaries, the Prolyse in Acute Cerebral Thromboembolism II (PROACT II) study published in 1999 showed some evidence of benefit if intra-arterial recombinant pro urokinase was administered to an occluding thrombus within MCA, subsequent studies were not so encouraging [69]. Yet, in 2015, mechanical thrombectomy (MT) and its benefit as a breakthrough in the field of stroke management emerged with a sum of clinical trials as MR CLEAN, ESCAPE, REVASCAT, SWIFT-PRIME, and EXTEND-IA [76‐80].
Clinical results continued in the year 2016, and studies in the field of MT through different forms of techniques were released as THERAPY, and THRACE [81, 82].
In the year 2018, a new hope began to appear with the use of different radiological techniques that all aim to extend the window of acute stroke management as in the case of MR WITNESS, DAWN, WAKE-UP, and DEFUSE 3 trials. Further hopes to extend the tPA window appeared with ECASS 4 in 2018, and EXTEND in 2019 [83‐87].
Extending the time window for MT with associated large core infarction was also a new horizon in 2023/2024 in the ANGEL-ASPECT and SELECT 2 [89, 90].
In 2024, further breakthroughs in stroke trials appeared reflecting the role of artificial intelligence in stroke management, care quality, and outcome in the Golden Bridge II trial which no longer questions thrombectomy, thrombolysis, or bridging rather than presenting techniques that aid in better functional recovery as the use of artificial intelligence and machine learning in analysis of imaging and predicting outcome [91‐93].
Other approaches are also ongoing to enhance better and faster recognition besides favorable outcomes for stroke patients as applying new and faster thrombolytic agents such as tenecteplase in acute management [94], usage of new oral anticoagulants in secondary prevention especially in ESUS and lone atrial fibrillation, inventing novel ways such as mobile stroke units [95], training emergency medical services, using database registries to monitor and follow stroke care and its acute management [96], analyzing gaps in stroke care in different regions of the world and applying remote stroke management through telestroke as well as identifying gaps in management based on gender and age rather than stroke etiology [97‐99].
Conclusion
Discoveries in Stroke etiology and management are as far as mankind, the first stroke or apoplexy descriptions were about 2000 years BC and as we are in 2024 AD stroke is still an astonishing field with new techniques and management plans.
Acknowledgements
Not applicable.
Declarations
Ethics approval and consent to participate
All procedures performed in the study were in accordance with the ethical standards of the Faculty of Medicine, Ain Shams University Research and Ethical Committee. An approval from the local ethical committee of the faculty of medicine at Ain Shams University was obtained.
Consent for publication
Not applicable.
Competing interests
The author declares that there is no competing interest.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Engelhardt E. Cerebral localization of the mind and higher functions The beginnings. Dement Neuropsychol. 2018;12(3):321–5.PubMedPubMedCentralCrossRef
2.
Figueredo V. The ancient heart: what the heart meant to our ancestors. J Am Coll Cardiol. 2021;78(9):957–9.PubMedCrossRef
3.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):93–621.CrossRef
4.
Karenberg A. Historic review: select chapters of a history of stroke. Neurol Res Pract. 2020;2:34.PubMedPubMedCentralCrossRef
5.
York GK, Steinberg DA. Chapter 3: neurology in ancient Egypt. Handb Clin Neurol. 2010; 95: 29–36.
6.
Khuda I, Al-Shamrani F. Stroke medicine in antiquity: the Greek and Muslim contribution. J Family Community Med. 2018;25(3):143–7.PubMedPubMedCentralCrossRef
7.
Herrerín J, Sánchez MA, Ikram S. A possible stroke victim from pharaonic Egypt. World Neurosurg. 2022;165:664–7.CrossRef
8.
George MG. Risk factors for ischemic stroke in younger adults: a focused update. Stroke. 2020;51(3):729–35.PubMedPubMedCentralCrossRef
9.
van Middendorp JJ, Sanchez GM, Burridge AL. The Edwin Smith papyrus: a clinical reappraisal of the oldest known document on spinal injuries. Eur Spine J. 2010;19(11):1815–23.PubMedPubMedCentralCrossRef
10.
Barr J. Vascular medicine and surgery in ancient Egypt. J Vasc Surg. 2014;60(1):260–3.PubMedCrossRef
11.
Ebers papyrus, section 872, column 108/3–9, quoted in De Moulin D. Aneurysms in antiquity. Arch Chir Neerl, 1961; 13: 49–63.
12.
Allam AH, Thompson RC, Wann LS, Miyamoto MI, El-Din Ael-H, El-Maksoud GA, et al. Atherosclerosis in ancient Egyptian mummies: the Horus study. JACC Cardiovasc Imaging. 2011; 4(4): 315–327.
13.
Minelli S, Minelli P, Montinari MR. Reflections on Atherosclerosis: Lesson from the Past and Future Research Directions. J Multidiscip Healthc. 2020;13:621–33.PubMedPubMedCentralCrossRef
14.
Thomas GS, Wann LS, Allam AH, Thompson RC, Michalik DE, Sutherland ML, et al. Why did ancient people have atherosclerosis?: from autopsies to computed tomography to potential causes. Glob Heart. 2014;9(2):229–37.PubMedCrossRef
15.
Hajar R. Coronary heart disease: from mummies to 21st century. Heart Views. 2017;18(2):68–74.PubMedPubMedCentralCrossRef
Reynolds EH, Wilson JV. Neurology and psychiatry in Babylon. Brain. 2014;137(Pt 9):2611–9.PubMedCrossRef
19.
Roushdy T, Abdel Nasser A, Nasef A, Elbassiouny A, George J, Aref H. A clinical comparative analysis between expanded NIHSS and original NIHSS in posterior circulation ischemic stroke. J Clin Neurosci. 2023;114:77–80.PubMedCrossRef
20.
Akinyemi RO, Tiwari HK, Srinivasasainagendra V, Akpa O, Sarfo FS, Akpalu A, et al. Novel functional insights into ischemic stroke biology provided by the first genome-wide association study of stroke in indigenous Africans. Genome Med. 2024;16(1):25.PubMedPubMedCentralCrossRef
21.
Aref H, Maged M, Roushdy T, Shokri H, Hamid E, Cho B, et al. Whole exome sequencing in a sample of Egyptian patients with covert cerebral small vessel disease. Egypt J Neurol Psychiatry Neurosurg. 2024;60:38.CrossRef
22.
Ashrafian H. Familial stroke 2700 years ago. Stroke. 2010; 41(4): 187; e188.
23.
Wang Y, Fan YC, Xie CL, Zheng GQ. History of post-stroke epilepsy in ancient China. J Neurol. 2011;258(8):1555–8.PubMedCrossRef
24.
Masic I. On occasion of 800th anniversary of birth of Ibn al-Nafis–discoverer of cardiac and pulmonary circulation. Med Arh. 2010;64(5):309–13.PubMedCrossRef
25.
Triposkiadis F, Xanthopoulos A, Boudoulas KD, Giamouzis G, Boudoulas H, Skoularigis J. The interventricular septum: structure, function, dysfunction, and diseases. J Clin Med. 2022;11(11):3227.PubMedPubMedCentralCrossRef
26.
Shi F, Sha L, Li H, Tang Y, Huang L, Liu H, et al. Recent progress in patent foramen ovale and related neurological diseases: a narrative review. Front Neurol. 2023;14:1129062.PubMedPubMedCentralCrossRef
Coupland AP, Thapar A, Qureshi MI, Jenkins H, Davies AH. The definition of stroke. J R Soc Med. 2017;110(1):9–12.PubMedPubMedCentralCrossRef
29.
Cambridge University Press and Assessment: Cambridge Dictionary. 2024.
30.
Pandora P, Michael B, Shah E. From apoplexy to stroke. Age Ageing. 1997;26:331–7.CrossRef
31.
Bryan CS. New observations support William Osler’s rationale for systemic bloodletting. Proc (Bayl Univ Med Cent). 2019;32(3):372–6.PubMed
32.
Osier W. Principles and Practice of Medicine, editions 1–15. Edinburgh: D. Appleton and Co. (eds 1–4)/Philadelphia: Lea and Febiger (eds 5–15), 1892–1944.
33.
Kitagawa K. Blood pressure management for secondary stroke prevention. Hypertens Res. 2022;45:936–43.PubMedCrossRef
34.
Diener HC, Easton JD, Hart RG, Kasner S, Kamel H, Ntaios G. Review and update of the concept of embolic stroke of undetermined source. Nat Rev Neurol. 2022;18(8):455–65.PubMedCrossRef
35.
Perera KS, de Sa BD, Rao-Melacini P, Taylor A, Cheng A, Hankey GJ, et al. Evaluating rates of recurrent ischemic stroke among young adults with embolic stroke of undetermined source: The Young ESUS Longitudinal Cohort Study. JAMA Neurol. 2022;79(5):450–8.PubMedPubMedCentralCrossRef
36.
Roushdy T, Din M, Mohamed A, Ibrahem HK, Bedros RY, Hamid E. Concepts behind epilepsy among Egyptian patients Is it a disease or a possession? Epilepsy Res. 2021;177:106760.PubMedCrossRef
37.
Pożarowszczyk N, Kurkowska-Jastrzębska I, Sarzyńska-Długosz I, Nowak M, Karliński M. Reliability of the modified Rankin Scale in clinical practice of stroke units and rehabilitation wards. Front Neurol. 2023;14:1064642.PubMedPubMedCentralCrossRef
38.
Koehler U. Jean-Nicolas Corvisart (1755–1821) – Leibarzt Napoleons, Retter der Auenbruggerschen Perkussion und Pionier der Herzerkrankungen [Jean-Nicolas Corvisart (1755–1821) - Personal Physician of Napoleon, Preserver of Auenbrugger’s Chest Percussion and Founder of Modern Cardiology]. Pneumologie. 2021;75(7):536–8.PubMedCrossRef
39.
Baillieul S, Dekkers M, Brill AK, Schmidt MH, Detante O, Pépin JL, et al. Sleep apnoea and ischaemic stroke: current knowledge and future directions. Lancet Neurol. 2022;21(1):78–88.PubMedCrossRef
40.
Mälstam E, Asaba E, Åkesson E, Guidetti S, Patomella AH. The feasibility of make my day-a randomized controlled pilot trial of a stroke prevention program in primary healthcare. Int J Environ Res Public Health. 2023;20(19):6828.PubMedPubMedCentralCrossRef
41.
Aderinto N, AbdulBasit MO, Olatunji G, Adejumo T. Exploring the transformative influence of neuroplasticity on stroke rehabilitation: a narrative review of current evidence. Ann Med Surg (Lond). 2023;85(9):4425–32.PubMedCrossRef
42.
Engelhardt E. Apoplexy, cerebrovascular disease, and stroke: historical evolution of terms and definitions. Dement Neuropsychol. 2017;11(4):449–53.PubMedPubMedCentralCrossRef
Dumitrescu AM, Costea CF, Cucu AI, Dumitrescu GF, Turliuc MD, Scripcariu DV, et al. The discovery of the circle of Willis as a result of using the scientific method in anatomical dissection. Rom J Morphol Embryol. 2020;61(3):959–65.PubMedCrossRef
45.
Ota T. Revised concept of rete-like collateral formation: Rete mirabile does not exist in humans. Interv Neuroradiol. 2023;17:15910199231221294.CrossRef
46.
Zampieri F, ElMaghawry M, Zanatta A, Thiene G. Andreas Vesalius: celebrating 500 years of dissecting nature. Glob Cardiol Sci Pract. 2015;22(5):66.CrossRef
47.
Xiang J, Venkatesan S. The role of Vesalius and his contemporaries in the transfiguration of human anatomical science. J Anat. 2023;242(2):124–31.PubMedCrossRef
48.
Paraskevas G, Koutsouflianiotis K, Iliou K, Noussios G. Iulius Casserius, a relatively underestimated anatomist: his contributions to brain’s anatomy. Childs Nerv Syst. 2019;35(12):2243–8.PubMedCrossRef
49.
Bender M, Olivi A, Tamargo RJ. Iulius Casserius and the first anatomically correct depiction of the circulus arteriosus cerebri (of Willis). World Neurosurg. 2013;79(5–6):791–7.PubMedCrossRef
50.
Mahakul DJ, Agarwal J. Pentagon inside the circle of willis and the golden ratio. World Neurosurg. 2021;156:23–6.PubMedCrossRef
51.
Nitta N, Tsuji A. Unilateral rete mirabile in multiple intracranial arteries with ipsilateral agenesis of the internal carotid artery: a case report. J Med Case Rep. 2023;17(1):268.PubMedPubMedCentralCrossRef
52.
Žemla M. A balsamic mummy. The medical-alchemical panpsychism of Paracelsus, Intellectual History Review. 2024;34(1):75–90.CrossRef
53.
Zargaran A, Zarshenas MM, Karimi A, Yarmohammadi H, Borhani-Haghighi A. Management of stroke as described by Ibn Sina (Avicenna) in the Canon of Medicine. Int J Cardiol. 2013;169(4):233–7.PubMedCrossRef
54.
Libby P. The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease. Nat Rev Cardiol. 2021;18(10):683–4.PubMedCrossRef
55.
Passacquale G, Sharma P, Perera D, Ferro A. Antiplatelet therapy in cardiovascular disease: current status and future directions. Br J Clin Pharmacol. 2022;88(6):2686–99.PubMedCrossRef
56.
Desborough MJR, Keeling DM. The aspirin story - from willow to wonder drug. Br J Haematol. 2017;177(5):674–83.PubMedCrossRef
57.
Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - a concise summary. Vascul Pharmacol. 2019;113:1–8.PubMedCrossRef
58.
Allahham M, Lerman A, Atar D, Birnbaum Y. Why not dipyridamole: a review of current guidelines and re-evaluation of utility in the modern era. Cardiovasc Drugs Ther. 2022;36(3):525–32.PubMedCrossRef
59.
Baqi Y, Müller CE. Antithrombotic P2Y12 receptor antagonists: recent developments in drug discovery. Drug Discov Today. 2019;24(1):325–33.PubMedCrossRef
60.
de Havenon A, Sheth KN, Madsen TE, Johnston KC, Turan TN, Toyoda K, et al. Cilostazol for secondary stroke prevention: history, evidence, limitations, and possibilities. Stroke. 2021;52(10):635–45.CrossRef
61.
Patti G, Micieli G, Cimminiello C, Bolognese L. The role of clopidogrel in 2020: a reappraisal. Cardiovasc Ther. 2020;16:8703627.
62.
Sharifi-Rad J, Sharopov F, Ezzat SM, Zam W, Ademiluyi AO, Oyeniran OH, et al. An updated review on glycoprotein iib/iiia inhibitors as antiplatelet agents: basic and clinical perspectives. High Blood Press Cardiovasc Prev. 2023;30(2):93–107.PubMedCrossRef
63.
Zeinhom MG, Aref HM, El-Khawas H, Roushdy TM, Shokri HM, Elbassiouny A. A pilot study of the ticagrelor role in ischemic stroke secondary prevention. Eur Neurol. 2022;85(1):50–5.PubMedCrossRef
64.
Aref HM, El-Khawas H, Elbassiouny A, Shokri HM, Zeinhom MG, Roushdy TM. A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. Neurol Sci. 2023;44(2):765–71.PubMedCrossRef
65.
Fisher CM. Anticoagulant therapy in cerebral thrombosis and cerebral embolism. A national cooperative study, interim report. Neurology. 1961;11(4):119–31.CrossRef
66.
Ruff IM, Jindal JA. Use of heparin in acute ischemic stroke: is there still a role? Curr Atheroscler Rep. 2015;17(9):51.PubMedCrossRef
67.
Grotta JC. Fifty years of acute ischemic stroke treatment: a personal history. Cerebrovasc Dis. 2021;50(6):666–80.PubMedCrossRef
68.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24): 1581–1587.
69.
del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke PROACT Investigators Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29(1):4–11.PubMedCrossRef
70.
Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al, MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364(9431): 331–337.
71.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al, CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16): 1706–1717.
72.
Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007; 6(11): 961–969.
73.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.PubMedCrossRef
74.
Dengler R, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, et al, EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010; 9(2): 159–166.
75.
Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–9.PubMedCrossRef
76.
Fransen PS, Beumer D, Berkhemer OA, van den Berg LA, Lingsma H, van der Lugt A, et al. MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial. Trials. 2014;15:343.PubMedPubMedCentralCrossRef
77.
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372(11):1019–30.PubMedCrossRef
78.
Smith WS, Yan B. REVASCAT trial: further advancement in endovascular stroke therapy. Stroke. 2015;46(10):3012–3.PubMedCrossRef
79.
Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al, SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med. 2015; 372(24): 2285–2295.
80.
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al, EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015; 372(11): 1009–1018.
81.
Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, et al, THERAPY Trial Investigators. Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone. Stroke. 2016; 47(9): 2331–2338.
82.
Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al, THRACE investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol. 2016; 15(11): 1138–1147.
83.
Schwamm LH, Wu O, Song SS, Latour LL, Ford AL, Hsia AW, et al, MR WITNESS Investigators. Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. Ann Neurol. 2018; 83(5): 980–993.
84.
Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al, WAKE-UP Investigators. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018; 379(7): 611–622.
85.
Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al, DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018; 378(1): 11–21.
86.
Amiri H, Bluhmki E, Bendszus M, Eschenfelder CC, Donnan GA, Leys D, et al. European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND. Int J Stroke. 2016;11(2):260–7.PubMedCrossRef
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al, Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018; 379(3): 215–225.
89.
Huo X, Ma G, Tong X, Zhang X, Pan Y, Nguyen TN, et al, ANGEL-ASPECT Investigators. Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. N Engl J Med. 2023; 388(14): 1272–1283.
90.
Sarraj A, Hassan AE, Abraham MG, Ortega-Gutierrez S, Kasner SE, Hussain MS, et al, SELECT2 Investigators. Trial of Endovascular Thrombectomy for Large Ischemic Strokes. N Engl J Med. 2023; 388(14): 1259–1271.
91.
Zhang X, Ding L, Jing J, Gu HQ, Jiang Y, Meng X, et al. Effect of an artificial intelligence-based clinical decision support system on stroke care quality and outcomes in patients with acute ischemic stroke (Golden Bridge II): a cluster-randomized clinical trial. Presented at: International Stroke Conference; 2024; Abstract LB15.
92.
Li Z, Zhang X, Ding L, Jing J, Gu HQ, Jiang Y, et al. Rationale and design of the GOLDEN BRIDGE II: a cluster-randomised multifaceted intervention trial of an artificial intelligence-based cerebrovascular disease clinical decision support system to improve stroke outcomes and care quality in China. Stroke Vasc Neurol. 2024; 2:svn-2023–002411.
93.
Daidone M, Ferrantelli S, Tuttolomondo A. Machine learning applications in stroke medicine: advancements, challenges, and future prospectives. Neural Regen Res. 2024;19(4):769–73.PubMedCrossRef
94.
Albers GW, Jumaa M, Purdon B, Zaidi SF, Streib C, Shuaib A, et al, TIMELESS Investigators. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. N Engl J Med. 2024; 390(8): 701–711.
95.
Navi BB, Audebert HJ, Alexandrov AW, Cadilhac DA, Grotta JC. PRESTO (Prehospital Stroke Treatment Organization) Writing Group. Mobile Stroke Units: Evidence, Gaps, and Next Steps. Stroke. 2022; 53(6): 2103–2113.
96.
Asugba O, Sedani R, Mikulik R, Dale S, Vařecha M, Coughlan K, et al. How registry data are used to inform activities for stroke care quality improvement across 55 countries: A cross-sectional survey of Registry of Stroke Care Quality (RES-Q) hospitals. Eur J Neurol. 2024;31(1): e16024.CrossRef
97.
Roushdy T, Alet MJ, Lotlikar R, Ramage E, Ullberg T, Mosconi MG, et al. Applying the World Stroke Organization roadmap in planning a model for stroke service implementation in Matrouh Governorate-Egypt: a World Stroke Organization young future stroke leaders’ analytical study. Egypt J Neurol Psychiatry Neurosurg. 2023;59:150.CrossRef
98.
George J, Aref H, Nasser AA, Nasef A, Elbassiouny A, Roushdy T. Gender disparity versus equality in acute stroke: a Middle Eastern country hospital-based study. Egypt J Neurol Psychiatr Neurosurg. 2023;59(1):73.PubMedPubMedCentralCrossRef
99.
Nahas NE, Shokri H, Roushdy T, Dawood N, Zaki A, Farhoudi M, et al. Do stroke services still show sex differences? A multicenter study Neurol Sci. 2024;45(3):1097–108.PubMedCrossRef
Medizinischen Rat von Chatbots auf der Basis sogenannter künstlicher Intelligenz haben laut Umfragen bereits knapp die Hälfte aller Erwachsenen schon einmal eingeholt. Welche Chancen und Risiken birgt das?
Wer insgesamt zuversichtlicher aufs Leben blickt, trägt ein geringeres Risiko, später einmal an Demenz zu erkranken als pessimistischere Zeitgenossen. Dafür sprechen zumindest Ergebnisse einer Längsschnittdatenanalyse aus den USA. Ob mehr Optimismus allerdings tatsächlich einer Demenz vorbeugt, bleibt unklar.
Eine hochdosierte Influenza-Vakzine geht mit einer verzögerten Demenzdiagnose einher. Darauf deutet eine Auswertung von US-Gesundheitsdaten hin. Besonders auffällig sind die Effekte in den ersten Monaten nach der Impfung.
Intensive Senkung eines erhöhten Blutdrucks kann nach einer intrazerebralen Blutung die funktionelle Erholung verbessern – mutmaßlich über eine Reduktion der Hämatomausdehnung. Offenbar hängt das aber vom Ausgangsvolumen ab, wie eine Analyse ergeben hat.
